NRX Pharmaceuticals, Inc. Common Stock

NRx Pharmaceuticals announced the pricing of an underwritten public offering of 5.7 million shares at $3.50 per share, expected to raise approximately $20 million (or $23 million with full underwriter option). The clinical-stage biopharmaceutical company plans to use net proceeds for working capital and general corporate purposes. The offering is...

NRx Pharmaceuticals announced a proposed underwritten public offering of common stock, causing shares to plummet 19.05% to $3.74 in after-hours trading on Tuesday. The clinical-stage biopharmaceutical company, which develops treatments for CNS disorders including suicidal depression and PTSD, plans to use the net proceeds for working capital and ...

With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a specul...

NRx Pharmaceuticals reported Q1 2026 financial results showing a net loss of $1.4 million, improved from $5.5 million in Q1 2025. The company advanced its preservative-free ketamine ANDA toward FDA approval expected in Q3 2026, initiated commercial manufacturing, and received FDA clearance for a Phase 2b/3 trial of NRX-101 combined with robotic-a...

NRx Pharmaceuticals announced it will release its first quarter 2026 financial results on May 18, 2026, followed by a conference call. The clinical-stage biopharmaceutical company is developing NMDA platform-based therapeutics for CNS disorders, with NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) in d...